Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 41

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC

Zhang, Yaqun, Xu, Lingfan, Chang, Yan, Li, YanJing, Butler, William, Jin, Er, Wang, Aifen, Tao, Yulei, Chen, Xufeng, Liang, Chaozhao, Huang, Jiaoti · 2020 · Prostate Cancer and Prostatic Diseases

Abstract

p53 is a tumor suppressor that prevents cancer onset and progression, and mutations in the p53 gene cause loss of the tumor suppressor function of the protein. The mutant p53 protein in tumor cells can form aggregates which contribute to the dominant-negative effect over the wild-type p53 protein, causing loss of p53 tumor suppression or gain of novel oncogenic functions. Mutations in p53 have been implicated in the pathogenesis of primary prostate cancer (PCa), and are often detected in recurrent and metastatic disease. Thus, targeting mutant p53 may constitute an alternative therapeutic strategy for advanced PCa for which there are no other viable options. In this study, we used immunoprecipitation, immunofluorescence, clonogenic survival, and cell proliferation assays, flow cytometric analysis and in vivo xenograft to investigate the biological effects of ReACp53, a cell-permeable peptide inhibitor of p53 aggregation, on mutant p53-carrying PCa cells. Our results show that ReACp53 targets amyloid aggregates of mutant p53 protein and restores the p53 nuclear function as transcriptional factor, induces mitochondrial cell death and reduces DNA synthesis of mutant p53-carrying PCa cells; ReACp53 also inhibits xenograft tumor growth in vivo. The data presented here suggest a therapeutic potential of targeting mutant p53 protein in advanced PCa setting, which has a clinical impact for aggressive PCa with transforming how such tumors are managed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41391-019-0172-z

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 44

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. https://doi.org/10.3322/caac.21332 . · DOI · Paper page
  2. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685–9. https://doi.org/10.1038/ng.2279 . · DOI · Paper page
  3. Vousden KH, Prives C. Blinded by the light: the growing complexity ofp53. Cell. 2009;137:413–31. https://doi.org/10.1016/j.cell.2009.04.037 . · DOI · Paper page
  4. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013;41(Database issue):D962–9. https://doi.org/10.1093/nar/gks1033 . · DOI · Paper page
  5. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol. 2010;2:a001016 https://doi.org/10.1101/cshperspect.a001016 . · DOI · Paper page
  6. He C, Li L, Guan X, Xiong L, Miao X. Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy. Chemotherapy. 2017;62:43–53. https://doi.org/10.1159/000446361 . · DOI
  7. Okorokov AL, Sherman MB, Plisson C, Grinkevich V, Sigmundsson K, Selivanova G, et al. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J. 2006;25:5191–200. https://doi.org/10.1038/sj.emboj.7601382 . · DOI · Paper page
  8. Silva JL, De Moura Gallo CV, Costa DC, Rangel LP. Prion-like aggregation of mutant p53 in cancer. Trends Biochem Sci. 2014;39:260–7. https://doi.org/10.1016/j.tibs.2014.04.001 . · DOI · Paper page
  9. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008;77:557–82. https://doi.org/10.1146/annurev.biochem.77.060806.091238 . · DOI · Paper page
  10. Sabapathy K. The Contrived Mutant p53 Oncogene - Beyond Loss of Functions. Front Oncol. 2015;5:276 https://doi.org/10.3389/fonc.2015.00276 . · DOI
  11. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2–8. https://doi.org/10.1038/ncb2641 . · DOI · Paper page
  12. Lei J, Qi R, Wei G, Nussinov R, Ma B. Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant. Phys Chem Chem Phys. 2016;18:8098–107. https://doi.org/10.1039/c5cp06538k . · DOI
  13. Costa DC, de Oliveira GA, Cino EA, Soares IN, Rangel LP, Silva JL. Aggregation and prion-like properties of misfolded tumor suppressors: is cancer a prion disease? Cold Spring Harb Perspect Biol. 2016;8. https://doi.org/10.1101/cshperspect.a023614 . · DOI
  14. Stindt MH, Muller PA, Ludwig RL, Kehrloesser S, Dotsch V, Vousden KH. Functional interplay between MDM2, p63/p73 and mutant p53. Oncogene. 2015;34:4300–10. https://doi.org/10.1038/onc.2014.359 . Epub 2014/11/25. · DOI
  15. Rangel LP, Costa DC, Vieira TC, Silva JL. The aggregation of mutant p53 produces prion-like properties in cancer. Prion. 2014;8:75–84. · DOI
  16. Stefani M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta. 2004;1739:5–25. https://doi.org/10.1016/j.bbadis.2004.08.004 . · DOI · Paper page
  17. Silva JL, Vieira TC, Gomes MP, Bom AP, Lima LM, Freitas MS, et al. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins. Acc Chem Res. 2010;43:271–9. https://doi.org/10.1021/ar900179t . · DOI
  18. Ano Bom AP, Rangel LP, Costa DC, de Oliveira GA, Sanches D, Braga CA, et al. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem. 2012;287:28152–62. https://doi.org/10.1074/jbc.M112.340638 . · DOI · Paper page
  19. Levy CB, Stumbo AC, Ano Bom AP, Portari EA, Cordeiro Y, Silva JL, et al. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int J Biochem Cell Biol. 2011;43:60–4. https://doi.org/10.1016/j.biocel.2010.10.017 . · DOI · Paper page
  20. Higashimoto Y, Asanomi Y, Takakusagi S, Lewis MS, Uosaki K, Durell SR, et al. Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry. 2006;45:1608–19. https://doi.org/10.1021/bi051192j . · DOI · Paper page
  21. Rigacci S, Bucciantini M, Relini A, Pesce A, Gliozzi A, Berti A, et al. The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys J. 2008;94:3635–46. https://doi.org/10.1529/biophysj.107.122283 . · DOI
  22. Ishimaru D, Andrade LR, Teixeira LS, Quesado PA, Maiolino LM, Lopez PM, et al. Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry. 2003;42:9022–7. https://doi.org/10.1021/bi034218k . PubMed PMID: 12885235 · DOI · Paper page
  23. Gregory CW, Johnson RT Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61:2892–8. Epub 2001/04/18.
  24. Chen X, Wong JY, Wong P, Radany EH. Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol cancer Res: MCR. 2011;9:448–61. https://doi.org/10.1158/1541-7786.MCR-10-0471 . Epub 2011/02/10 · DOI
  25. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54:2577–81.
  26. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, et al. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res. 2003;63:2905–12.
  27. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003;57:205–25. https://doi.org/10.1002/pros.10290 . · DOI · Paper page
  28. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011;71:1668–79. https://doi.org/10.1002/pros.21383 . · DOI · Paper page
  29. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2;–fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 1994;9:2523–9.
  30. Burch LR, Midgley CA, Currie RA, Lane DP, Hupp TR. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Lett. 2000;472:93–8. · DOI
  31. Matsumoto M, Furihata M, Ohtsuki Y. Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol. 2006;39:79–87. https://doi.org/10.1007/s00795-006-0320-0 . · DOI
  32. Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140:3079–93. https://doi.org/10.1242/dev.091744 . · DOI · Paper page
  33. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated byp53. Neoplasia. 2007;9:1152–9. · DOI
  34. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–58. https://doi.org/10.1126/science.1235122 . · DOI · Paper page
  35. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA. 2006;103:18238–42. https://doi.org/10.1073/pnas.0607057103 . · DOI · Paper page
  36. Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci USA. 2014;111:11139–44. https://doi.org/10.1073/pnas.1411446111 . · DOI · Paper page
  37. Soundararajan R, Aparicio AM, Logothetis CJ, Mani SA, Maity SN. Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol. 2018;8:69 https://doi.org/10.3389/fonc.2018.00069 . · DOI
  38. Tsai HK, Lehrer J, Alshalalfa M, Erho N, Davicioni E, Lotan TL. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer. 2017;17:759 https://doi.org/10.1186/s12885-017-3729-z . · DOI
  39. Khemlina G, Ikeda S, Kurzrock R. Molecular landscape of prostate cancer: implications for current clinical trials. Cancer Treat Rev. 2015;41:761–6. https://doi.org/10.1016/j.ctrv.2015.07.001. · DOI
  40. Kluth M, Harasimowicz S, Burkhardt L, Grupp K, Krohn A, Prien K, et al. Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. Int J Cancer. 2014;135:1369–80. https://doi.org/10.1002/ijc.28784 . · DOI
  41. Chen H, Sun Y, Wu C, Magyar CE, Li X, Cheng L, et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer. 2012;19:321–31. https://doi.org/10.1530/ERC-11-0368 . · DOI
  42. Guseva NV, Rokhlin OW, Bair TB, Glover RB, Cohen MB. Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor. Oncotarget. 2012;3:183–94. https://doi.org/10.18632/oncotarget.449 . · DOI
  43. Zhang Y, Hu Y, Wang JL, Yao H, Wang H, Liang L, et al. Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp. Oncogene. 2017;36:5473–83. https://doi.org/10.1038/onc.2017.152 . · DOI
  44. Wang G, Fersht AR. Multisite aggregation of p53 and implications for drug rescue. Proc Natl Acad Sci USA. 2017;114:E2634–E43. https://doi.org/10.1073/pnas.1700308114 . · DOI · Paper page

Cited by

See all 41

Metadata

Authors
Zhang, Y., Xu, L., Chang, Y., Li, Y., Butler, W., Jin, E., Wang, A., Tao, Y., Chen, X., Liang, C., & Huang, J.
Venue
Prostate Cancer and Prostatic Diseases
Published
2019-08-30
Volume
23
Issue
1
Pages
160-171
ISSN
  • 1365-7852
  • 1476-5608
Cited by
41
References
5
Language
en
Licence
Funders
Foundation for the National Institutes of Health (1R01CA172603, 1R01CA181242)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. https://app.cochat.ai/papers/10.1038/s41391-019-0172-z
The paper
Zhang, Y., Xu, L., Chang, Y., Li, Y., Butler, W., Jin, E., Wang, A., Tao, Y., Chen, X., Liang, C., & Huang, J. (2020). Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-019-0172-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.